-
Asciminib, sold
under the
brand name Scemblix, is a
medication used to
treat Philadelphia chromosome-positive
chronic myeloid leukemia (Ph+ CML). Asciminib...
- (CML) with resistance, or
intolerance to
prior therapy.[citation needed]
Asciminib (Scemblix) was
approved for
medical use in the
United States in October...
-
November 2020.
Retrieved 16
October 2019. "FDA
approves Novartis Scemblix® (
Asciminib), with
novel mechanism of
action for the
treatment of
chronic myeloid...
-
Dasatinib L01EA03
Nilotinib L01EA04
Bosutinib L01EA05
Ponatinib L01EA06
Asciminib L01EB01
Gefitinib L01EB02
Erlotinib L01EB03
Afatinib L01EB04 Osimertinib...
- 1
clinical trial of
combination therapy for
metastatic breast cancer.
Asciminib (ABL001) is an
inhibitor of the
Abelson kinase targeting the myristoyl...
- (Tykerb)
Nilotinib (Tasigna)
Bosutinib (Bosulif)
Ponatinib (Iclusig)
Asciminib (Scemblix)
Bortezomib (Velcade) is an apoptosis-inducing
proteasome inhibitor...
- BCR::ABL1 TKI
Generation Imatinib First-generation Dasatinib, Nilotinib,
Bosutinib Second-generation Ponatinib,
Asciminib Third-generation...
- Niemann-Pick
disease type C (NPC) in
people aged two
years of age and
older Asciminib Novartis Treatment of
adults with
newly diagnosed Philadelphia chromosomepositive...
-
Cabozantinib (VEGFR), Capmatinib,
Crizotinib (ALK) Non-receptor bcr-abl
Asciminib Bosutinib Dasatinib Imatinib Nilotinib Ponatinib Radotinib Src (Bosutinib...
-
Cabozantinib (VEGFR), Capmatinib,
Crizotinib (ALK) Non-receptor bcr-abl
Asciminib Bosutinib Dasatinib Imatinib Nilotinib Ponatinib Radotinib Src (Bosutinib...
